167 related articles for article (PubMed ID: 34787026)
21. Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-existing NRTI Resistance.
Acosta RK; Willkom M; Andreatta K; Liu H; Martin R; Parvangada A; Martin H; Collins S; White KL
J Acquir Immune Defic Syndr; 2020 Nov; 85(3):363-371. PubMed ID: 32701823
[TBL] [Abstract][Full Text] [Related]
22. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial.
Venter WDF; Sokhela S; Simmons B; Moorhouse M; Fairlie L; Mashabane N; Serenata C; Akpomiemie G; Masenya M; Qavi A; Chandiwana N; McCann K; Norris S; Chersich M; Maartens G; Lalla-Edward S; Vos A; Clayden P; Abrams E; Arulappan N; Hill A
Lancet HIV; 2020 Oct; 7(10):e666-e676. PubMed ID: 33010240
[TBL] [Abstract][Full Text] [Related]
23. Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus.
Sax PE; Rockstroh JK; Luetkemeyer AF; Yazdanpanah Y; Ward D; Trottier B; Rieger A; Liu H; Acosta R; Collins SE; Brainard DM; Martin H;
Clin Infect Dis; 2021 Jul; 73(2):e485-e493. PubMed ID: 32668455
[TBL] [Abstract][Full Text] [Related]
24. Real-life data of immune recovery using bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed people living with HIV. Results at 48-96 weeks of RETROBIC Study.
Troya J; Pousada G; Micán R; Galera C; Sanz J; de Los Santos I; Dueñas C; Cabello N; Martín C; Galindo MJ; Garcinuño MÁ; Pedrero-Tomé R; Buzón L
J Antimicrob Chemother; 2024 Mar; 79(3):595-607. PubMed ID: 38267266
[TBL] [Abstract][Full Text] [Related]
25. Brief Report: Bictegravir/Emtricitabine/Tenofovir Alafenamide Efficacy in Participants With Preexisting Primary Integrase Inhibitor Resistance Through 48 Weeks of Phase 3 Clinical Trials.
D'Antoni ML; Andreatta K; Acosta R; Martin H; Chang S; Martin R; White KL
J Acquir Immune Defic Syndr; 2022 Apr; 89(4):433-440. PubMed ID: 34897227
[TBL] [Abstract][Full Text] [Related]
26. Crushed vs dissolved bictegravir/emtricitabine/tenofovir alafenamide.
Johnson TM; Rivera CG
Am J Health Syst Pharm; 2023 Feb; 80(4):180-181. PubMed ID: 36377971
[No Abstract] [Full Text] [Related]
27. Bictegravir/emtricitabine/tenofovir alafenamide ensures high rates of virological suppression maintenance despite previous resistance in PLWH who optimize treatment in clinical practice.
Armenia D; Forbici F; Bertoli A; Berno G; Malagnino V; Gagliardini R; Borghi V; Gennari W; Cicalini S; Buonomini A; Teti E; Lanini S; Latini A; Sarmati L; Mussini C; Andreoni M; Antinori A; Perno CF; Ceccherini-Silberstein F; Santoro MM
J Glob Antimicrob Resist; 2022 Sep; 30():326-334. PubMed ID: 35793776
[TBL] [Abstract][Full Text] [Related]
28. [Real-world efficacy of switching to bictegravir/ emtricitabine/tenofovir alafenamide in pretreated patients with triple therapy containing rilpivirine].
de Gea Grela A; Martín Carbonero L; Micán R; Bernardino JI; Ramos L; Valencia ME
Rev Esp Quimioter; 2022 Aug; 35(4):378-381. PubMed ID: 35614862
[TBL] [Abstract][Full Text] [Related]
29. Short Communication: Comparing Lamivudine+Dolutegravir and Bictegravir/Emtricitabine/Tenofovir Alafenamide as Switch Strategies: Preliminary Results from Clinical Practice.
Baldin G; Ciccullo A; Lombardi F; D'Angelillo A; Dusina A; Emiliozzi A; Farinacci D; Moschese D; Picarelli C; Borghetti A; Di Giambenedetto S
AIDS Res Hum Retroviruses; 2021 Jun; 37(6):429-432. PubMed ID: 33280486
[TBL] [Abstract][Full Text] [Related]
30. Rapid ART initiation with bictegravir/emtricitabine/tenofovir alafenamide in individuals presenting with advanced HIV disease (Rainbow study).
Camici M; Gagliardini R; Lanini S; Del Duca G; Mondi A; Ottou S; Plazzi MM; De Zottis F; Pinnetti C; Vergori A; Grilli E; Mastrorosa I; Mazzotta V; Paulicelli J; Bellagamba R; Cimini E; Tartaglia E; Notari S; Tempestilli M; Cicalini S; Amendola A; Abbate I; Forbici F; Fabeni L; Girardi E; Vaia F; Maggi F; Antinori A
Int J Antimicrob Agents; 2024 Jan; 63(1):107049. PubMed ID: 38056572
[TBL] [Abstract][Full Text] [Related]
31. High efficacy of switching to bictegravir/emtricitabine/tenofovir alafenamide in people with suppressed HIV and preexisting M184V/I.
Sax PE; Andreatta K; Molina JM; Daar ES; Hagins D; Acosta R; D'Antoni ML; Chang S; Martin R; Liu H; Blair C; McNicholl I; Gallant J; Collins SE; Martin H; White KL
AIDS; 2022 Sep; 36(11):1511-1520. PubMed ID: 35466963
[TBL] [Abstract][Full Text] [Related]
32. A Concept Evaluation Study of a New Combination Bictegravir plus Tenofovir Alafenamide Nanoformulation with Prolonged Sustained-Drug-Release Potency for HIV-1 Preexposure Prophylaxis.
Mandal S; Prathipati PK; Sunagawa SW; Destache CJ
Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33526487
[TBL] [Abstract][Full Text] [Related]
33. Short-course daily isoniazid and rifapentine for latent tuberculosis infection in people living with HIV who received coformulated bictegravir/emtricitabine/tenofovir alafenamide.
Liou BH; Cheng CN; Lin YT; Lin YJ; Chuang YC; Lin KY; Liu WC; Lin SW; Kuo CH; Sun HY; Hung CC
J Int AIDS Soc; 2021 Nov; 24(11):e25844. PubMed ID: 34822220
[TBL] [Abstract][Full Text] [Related]
34. Short-term neuropsychiatric tolerability of bictegravir combined with emtricitabine/tenofovir alafenamide in clinical practice.
Hoffmann C; Schewe K; Fenske S; Buhk T; Sabranski M; Adam A; Hansen S; Stellbrink HJ
Antivir Ther; 2020; 25(2):83-90. PubMed ID: 32235038
[TBL] [Abstract][Full Text] [Related]
35. Increased human immunodeficiency virus viral load with cerebral infarction due to varicella zoster virus vasculopathy on treatment with bictegravir/emtricitabine/tenofovir alafenamide suspension: a case report and literature review.
Ishikawa K; Kawai F; Mori N
AIDS Res Ther; 2023 Jul; 20(1):53. PubMed ID: 37518182
[TBL] [Abstract][Full Text] [Related]
36. Crushed bictegravir/emtricitabine/tenofovir alafenamide in a human immunodeficiency virus-positive patient with esophageal cancer.
Fulco PP
Am J Health Syst Pharm; 2020 Mar; 77(7):509-510. PubMed ID: 32207818
[No Abstract] [Full Text] [Related]
37. Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection.
Deeks ED
Drugs; 2018 Nov; 78(17):1817-1828. PubMed ID: 30460547
[TBL] [Abstract][Full Text] [Related]
38. [Effectiveness, safety, and economic impact of the bictegravir/emtricitabine/tenofovir alafenamide regimen in real clinical practice cohort of HIV-1 infected adult patients].
Gutiérrez-Lorenzo M; Rubio-Calvo D; Urda-Romacho J
Rev Esp Quimioter; 2021 Aug; 34(4):315-319. PubMed ID: 34032111
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial.
Daar ES; DeJesus E; Ruane P; Crofoot G; Oguchi G; Creticos C; Rockstroh JK; Molina JM; Koenig E; Liu YP; Custodio J; Andreatta K; Graham H; Cheng A; Martin H; Quirk E
Lancet HIV; 2018 Jul; 5(7):e347-e356. PubMed ID: 29925490
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial.
Gallant JE; Daar ES; Raffi F; Brinson C; Ruane P; DeJesus E; Johnson M; Clumeck N; Osiyemi O; Ward D; Morales-Ramirez J; Yan M; Abram ME; Plummer A; Cheng AK; Rhee MS
Lancet HIV; 2016 Apr; 3(4):e158-65. PubMed ID: 27036991
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
